Waldencast (WALD) CFO receives 79,289 shares as Obagi unit sold

Rhea-AI Filing Summary

Waldencast plc’s Chief Financial Officer, Manuel Manfredi, reported the accelerated vesting and settlement of 79,289 restricted stock units (RSUs) into the same number of Class A ordinary shares on July 30, 2026. This occurred upon completion of Waldencast’s sale of its Obagi Medical dermatological skincare and aesthetics business, after which he transitioned to lead Obagi Medical. Following the settlement, he directly holds 118,933 Class A ordinary shares. A prior grant of 118,933 RSUs dated October 30, 2024 had originally been scheduled to vest in three annual tranches.

Insider Trade Summary

Net Buyer: 79,289 shares

Net Buy 2 txns

Insider Manfredi Manuel

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F2, F1, F3	79,289	$0.00	$0.00
Exercise	Class A Ordinary Shares F1	79,289	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Class A Ordinary Shares — 118,933 shares (Direct)

Footnotes (3)

1. F1. Represents accelerated vesting of 79,289 outstanding restricted stock units ("RSUs") held by the reporting person in connection with the completion of the Issuer's sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective on the date of completion of such sale, the reporting person transitioned from the Issuer to lead Obagi Medical.
2. F2. Each RSU represents a contingent right to receive one Class A ordinary share, or an equivalent value in cash at the plan administrator's election.
3. F3. On October 30, 2024, the reporting person was granted 118,933 RSUs, which would have vested over a three-year period as follows: (i) 39,644 on October 1, 2025; (ii) 39,644 on October 1, 2026; and (iii) 39,645 on October 1, 2027.

Key Figures

RSUs vested and settled: 79,289 units Shares held after transaction: 118,933 shares Original RSU grant: 118,933 units +3 more

6 metrics

RSUs vested and settled 79,289 units Accelerated vesting and conversion to Class A ordinary shares on July 30, 2026

Shares held after transaction 118,933 shares Direct Class A ordinary shares owned by the CFO following settlement

Original RSU grant 118,933 units RSUs granted to the CFO on October 30, 2024

First scheduled vesting tranche 39,644 units Originally scheduled to vest on October 1, 2025

Second scheduled vesting tranche 39,644 units Originally scheduled to vest on October 1, 2026

Third scheduled vesting tranche 39,645 units Originally scheduled to vest on October 1, 2027

Key Terms

Restricted Stock Units, accelerated vesting, Class A ordinary share, contingent right

4 terms

Restricted Stock Units financial

"Represents accelerated vesting of 79,289 outstanding restricted stock units ("RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

accelerated vesting financial

"Represents accelerated vesting of 79,289 outstanding restricted stock units"

A contract feature that makes stock awards, options, or restricted shares become owned or exercisable earlier than the original schedule. It shortens or cancels the waiting period so recipients can sell, transfer, or exercise their equity sooner — think of a timed lock that is unlocked ahead of schedule. It matters to investors because it changes when shares enter the market, who controls them, and how much dilution or ownership concentration happens.

Class A ordinary share financial

"Each RSU represents a contingent right to receive one Class A ordinary share"

A Class A ordinary share is a type of common stock a company issues that carries a specific set of rights—most often particular voting power, dividend terms, or transfer rules—distinct from other share classes. For investors it matters because those rights affect control over company decisions, how income is paid out, and how easy shares are to buy or sell; think of it like a tiered ticket that gives different access and influence at the same event.

contingent right financial

"Each RSU represents a contingent right to receive one Class A ordinary share"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/07/2026 - 04:11 PM Accepted by SEC EDGAR 08/07/2026 - 04:10 PM Learn about SEC filing dates

FAQ

What insider transaction did Waldencast (WALD) report for its CFO?

Waldencast’s CFO, Manuel Manfredi, reported accelerated vesting and settlement of 79,289 RSUs into 79,289 Class A ordinary shares on July 30, 2026. These shares are now held directly, bringing his reported direct Class A ownership to 118,933 shares.

How many Waldencast (WALD) RSUs were originally granted to the CFO and on what schedule?

On October 30, 2024, the CFO was granted 118,933 RSUs, scheduled to vest over three years: 39,644 on October 1, 2025; 39,644 on October 1, 2026; and 39,645 on October 1, 2027, before the later acceleration event.

What triggered the accelerated RSU vesting for Waldencast (WALD)’s CFO?

The accelerated vesting of 79,289 RSUs was triggered by completion of Waldencast’s sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective that date, the CFO transitioned from Waldencast to lead Obagi Medical.

What is the Waldencast (WALD) CFO’s Class A shareholding after this Form 4 transaction?

After settlement of the RSUs, Waldencast’s CFO directly owns 118,933 Class A ordinary shares. This post-transaction figure comes from the reported total shares following the acquisition of 79,289 Class A shares linked to the accelerated RSU vesting.

Were the Waldencast (WALD) CFO transactions made under a Rule 10b5-1 trading plan?

The report’s Rule 10b5-1 checkbox is not marked as affirmative, indicating the company did not characterize these transactions as executed under a Rule 10b5-1 trading plan. No footnote describes them as pursuant to a pre-arranged trading plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Manfredi Manuel

(Last) (First) (Middle)

C/O WALDENCAST PLC

MICHELIN HOUSE, 81 FULHAM ROAD

(Street)

LONDON SW3 6RD

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Waldencast plc [ WALD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	07/30/2026		M(1)		79,289	A	$0	118,933	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	07/30/2026		M(1)			79,289	(3)	(3)	Class A Ordinary Shares	79,289	$0	0	D

Explanation of Responses:

1. Represents accelerated vesting of 79,289 outstanding restricted stock units ("RSUs") held by the reporting person in connection with the completion of the Issuer's sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective on the date of completion of such sale, the reporting person transitioned from the Issuer to lead Obagi Medical.

2. Each RSU represents a contingent right to receive one Class A ordinary share, or an equivalent value in cash at the plan administrator's election.

3. On October 30, 2024, the reporting person was granted 118,933 RSUs, which would have vested over a three-year period as follows: (i) 39,644 on October 1, 2025; (ii) 39,644 on October 1, 2026; and (iii) 39,645 on October 1, 2027.

Remarks:

	/s/ Manuel Manfredi	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)